MarketPeel
Insider Trading Intelligence
FJ

Filip Janku

GLUE
CHIEF MEDICAL OFFICER · MONTE ROSA THERAPEUTICS, INC. · CIK 0001862930
FILING MIX · LIFETIME60%/40%
BUYS
15
SELLS
10
TOTAL VALUE
$1.77M
COMPANIES
1
ACTIVE SINCE
Jun 2021
HOLDINGS NOW
66,019
AVG SELL PX
$21.03
TRADE KIND
SHOWING 25 / 25
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Filip Janku, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-5.18%+0.58%-5.76%-5.76%
14d1+100.00%-9.48%-0.60%-8.88%-8.88%
30d1+100.00%-19.48%-3.75%-15.73%-15.73%
60d1+0.00%+1.44%+4.62%-3.19%-3.19%
90d1+100.00%-3.59%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GLUE · 66,019 shares · as of Jun 30, 2026
096,767193,535290,302387,06920222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 15 buys / 10 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Medical Officer
5,407$13.41$72.5K66,019Jun 30, 2026Jul 1, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Medical Officer
5,40781,093Jun 30, 2026Jul 1, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,407$24.50$132.5K60,612Jun 30, 2026Jul 1, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Medical Officer
6,00060,000Jun 29, 2026Jun 30, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,000$22.95$137.7K59,992Jun 29, 2026Jun 30, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Medical Officer
6,000$7.56$45.4K65,992Jun 29, 2026Jun 30, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Medical Officer
30,000$7.56$226.8K89,992Jun 24, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
30,000$21.42$642.7K59,992Jun 24, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Medical Officer
30,00066,000Jun 24, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Medical Officer
6,00096,000Jun 23, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,845$20.22$239.5K59,992Jun 23, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
Chief Medical Officer
6,000$7.56$45.4K71,837Jun 23, 2026Jun 25, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Medical Officer
9,189$19.50$179.2K65,837Feb 23, 2026Feb 24, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
SALE
Chief Medical Officer
3,155$15.17$47.9K75,026Jan 5, 2026Jan 5, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,00078,181Jan 2, 2026Jan 5, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
139,000139,000Jan 2, 2026Jan 5, 2026View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,00045,189Jan 2, 2025Jan 6, 2025View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
161,000161,000Jan 2, 2025Jan 6, 2025View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,00030,000Sep 13, 2024Sep 13, 2024View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
121,000121,000Jan 2, 2024Jan 4, 2024View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
135,000135,000Jan 3, 2023Jan 4, 2023View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,00036,000Dec 15, 2022Dec 19, 2022View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,00036,000Oct 31, 2022Nov 1, 2022View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
86,50086,500Mar 1, 2022Mar 2, 2022View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
387,069387,069Jun 23, 2021Jun 25, 2021View →
Other insiders · GLUE
Loading peer insiders…
About this filer
CIK 0001862930
ROLE
Chief Medical Officer
PRIMARY
GLUE
COMPANIES
1
ACTIVE SINCE
Jun 2021
MARKETPEEL · /INSIDER/0001862930DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback